Anti-CEA fusion proteins (Cancer Research Technologies/Novozymes/University College London)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CEA fusion proteins (Cancer Research Technologies/Novozymes/University College London)

Drug Alias NameMFE 23-albumin fusion proteinMFE-23-albumin fusion proteinAnti-CEA scFv fusion proteinsMFE-23

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)

Mechanisms of ActionAnti-CEA

TargetsCarcinoembryonic antigen

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCancer Research Technology

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCancer Research Technology Novozymes University College London

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A